Maintaining Buy on NovoCure: Viewing CMS Billing Revocation as a Temporary Administrative Setback with Limited Long-Term Impact

NovoCure, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $39.00 price target.

Emily Bodnar has given his Buy rating due to a combination of factors that, in his view, leave the company’s long‑term outlook largely intact despite a temporary disruption. He interprets the CMS billing revocation as a paperwork- and process-related issue tied to routine revalidation for DME suppliers, not as a reflection of any clinical, safety, or quality shortcoming in NovoCure’s therapy. Based on CMS procedures and past outcomes for similar administrative cases, he expects the billing privileges to be restored within roughly one to three months, with a priority review request potentially expediting the timeline. Although he incorporates management’s estimate of about $13M in lost monthly revenue in 1Q26 into his model, he sees this as a near-term headwind rather than a structural impairment to the business.

Bodnar adjusts his 2026 revenue forecast modestly downward to reflect the anticipated ~$26M hit in the first quarter and only partial recovery of those lost billings thereafter, but he does not view this as materially changing NovoCure’s fundamental value proposition. He also notes the possibility that certain foregone CMS payments could be recouped through retroactive billing if the agency permits backdated claims once the issue is resolved. In his view, the company continues to treat patients and maintain operational continuity, supporting the thesis that the setback is technical and temporary. Taken together, the limited scope of the problem, the historical precedent for relatively swift resolution, and the company’s underlying business drivers justify maintaining a Buy rating on the stock despite the short-term volatility risk.

In another report released on January 30, Piper Sandler also reiterated a Buy rating on the stock with a $27.00 price target.